Sequoia Sciences is a pharmaceutical company discovering and developing new medicines for the treatment of bacterial infections and cancers. Our development programs consist of small molecules targeting bacterial infections and cancers, and also vaccines for the treatment and prevention of recurrent urinary tract infections. Sequoia is engaged in research and development programs and collaborations with laboratories, universities, clinical research sites, and private businesses. Our goal is to improve the quality of life for those individuals significantly affected by recurrent and chronic bacterial infections and cancers.
Recent Publications | See All
July, 2014: La Clair, J., Loveridge, S., Tenney, K., O'Neil-Johnson, M., Chapman, E., Crews, P., "In Situ Natural Product Discovery via an Artificial Marine Sponge." PLOS One, 2014, 9 (7), doi:10.1371/journal.pone.0100474
July, 2014: Zerbe, P., Chiang, A., Dullat, H., O'Neil-Johnson, M., Starks, C., Hamberger, B., Bohlmann, J., "Diterpene Synthases of the Biosynthetic System of Medicinally Active Diterpenoids in Marrubium vulgare,"
The Plant Journal, 2014, Accepted
June, 2014: Starks, C.M.; Norman, V.L.; Williams, R.B.; Goering, M.G.; Rice, S.M.; O'Neil-Johnson, M.A.; Eldridge, G.R. "Antibacterial Activity of Taxodium ascendens Diterpenes Against Methicillin-resistant Staphylococcus aureus." Natural Product Communications, 2014, 9 (8), 1129-1130
June, 2014: Kilgore, M., Rolf, M., Starks, C.M., O'Neil-Johnson, M., Kutchan, T.M., "Cloning and Characterization of a Norbelladine 4'-O-Methyltransferase Involved in the Biosynthesis of the Alzheimer's Drug Galanthamine in Narcissus spp." PLOS One, 2014, Accepted